Creative Enzymes, a global enzyme technology service provider, recently launched an AI-integrated platform that takes a systematic approach to accelerating enzyme development. By merging computational enzyme engineering with hands-on process development know-how, the platform delivers AI-Driven Biocatalysis Solutions that are predictable in silico and practical at industrial scale. While biocatalysis is an established manufacturing process, a significant gap remains between identifying application opportunities and having suitable enzymes available. Traditional development approaches cannot meet the speed requirements of iterative product development.
AI brings critical value on three fronts: predicting enzyme candidates best suited for a given biocatalytic reaction; designing enzymes constrained by process parameters rather than biological factors; and leveraging key molecular features to anticipate process performance in advance. The benefits extend beyond speed and efficiency. AI techniques reduce the need to experiment with numerous biocatalyst variants, saving on R&D costs. They also reduce the risk of process failure by identifying suitable biocatalysts earlier and opening routes to molecules previously inaccessible to enzymatic conversion.
The platform's capabilities are delivered through three specialized service modules. AI-Driven Industrial Biocatalysis addresses the journey from reaction engineering to full-scale implementation, including substrate concentration optimization, cofactor regeneration, and product inhibition management; immobilization and formulation development; integration of process analytical technology; and delivery of complete technology transfer packages. AI-Driven Green Biocatalysis provides sustainability-focused solutions that align with corporate environmental goals, as enzymatic reactions typically occur in aqueous media at room temperature, minimizing organic solvents and emissions. AI-guided development amplifies these advantages by identifying inherently more efficient enzymes.
The platform's effectiveness was demonstrated in a recent case study on transaminase engineering. Researchers developed a 6D protein engineering framework combining interaction energy, solvent effects, and 1.39 million structural fragments to predict beneficial mutations. Five AI-selected transaminase variants—each with nine mutations—exhibited high solubility and catalytic stability at 7-liter fermentation scale. The engineered enzymes convert prochiral ketones to sitagliptin, delivering enantiomeric purity exceeding 99% and conversion rates of up to 89% during scale-up production.
Pharmaceuticals are currently the biggest adopter of AI biocatalysis, particularly for asymmetric synthesis of chiral intermediates and replacing hazardous reagents. Agrochemicals and food industries are also adopting the technology to fine-tune toxicology profiles and deliver cleaner labels through enzymatic modification. Fine chemicals and personal care sectors are exploring high-value conversions and milder, more sustainable processes. For moderately complex targets, this structured approach reduces the "design-build-test-learn" cycle from 12–24 months to just 8–12 months.
